AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20463100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (100 microg) plus placebo
Number of subjects: 99
Study 20463100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) and calcium
Number of subjects: 99
Study 20463100 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium load (600 mg of calcium carbonate)
Number of subjects: 99
Study 20463100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (100 microg)
Number of subjects: 99
Study 20463100 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 99
Study 18771766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 150
Study 18771766 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 150
Study 18771766 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy Hysterectomy (MiniLPT)
Number of subjects: 150
Study 16636233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematoma growth
Number of subjects: 218
Study 16636233 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage hematoma growth
Number of subjects: 218
Study 16636233 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ICH volume
Number of subjects: 218
Study 16636233 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (GCS)
Number of subjects: 218
Study 16636233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular hemorrhage (IVH)
Number of subjects: 218
Study 16636233 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage growth
Number of subjects: 218
Study 16636233 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 218
Study 12816288 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with anti-infective therapy (metronidazole gel, chlorhexidine gluconate 0.2%, doxycycline 100 mg x 1/day for 6 to 8 weeks, ibuprofen 3 x 400 mg/day for 7 days)
Number of subjects: 38
Study 12816288 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR) without anti-infective therapy (chlorhexidine gluconate 0.2% for 1 week, doxycycline 100 mg x 1/day for 1 week, ibuprofen 3 x 400 mg/day for 7 days)
Number of subjects: 38
Study 12816288 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of new tissue growth at retrieval
Number of subjects: 38
Study 10519578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral 1% unpreserved lidocaine combined with topical anesthesia (oxybuprocaine)
Number of subjects: 200
Study 10519578 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia with 6 ml prilocaine
Number of subjects: 200
Study 10519578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral 1% unpreserved lidocaine
Number of subjects: 200
Study 7661884 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL subclass pattern B
Number of subjects: 92
Study 7661884 — intervention group
Group type: COMPARATOR
Intervention: LDL subclass pattern A
Number of subjects: 92
Study 2477130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 to 160 mg bid)
Number of subjects: 18
Study 2477130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2477130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 to 160 mg bid) in phase 2
Number of subjects: 18
Study 1261197 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 fractions of radiation
Number of subjects: 0
Study 1261197 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 fractions of radiation
Number of subjects: 0
Study 1261197 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 fractions of radiation
Number of subjects: 0
Study 30571546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17β‐estradiol per day
Number of subjects: 20
Study 30571546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2+2 mg 17β‐estradiol per day
Number of subjects: 20
Study 30571546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30571546 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age‐matched young women)
Number of subjects: 20
Study 28363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes 'CNFC 10762', 'IAC Dawn', and 'BRS Style'
Number of subjects: 0
Study 28363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis using Euclidean distance
Number of subjects: 0
Study 28363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Yield grain character
Number of subjects: 0
Study 28363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrids with high heterotic effect
Number of subjects: 0
Study 27063130 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon high torque appliances
Number of subjects: 40
Study 27063130 — intervention group
Group type: COMPARATOR
Intervention: MBT straight wire appliance
Number of subjects: 40
Study 24002519 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT intervention (centralized, nurse-delivered telephone-based service)
Number of subjects: 775
Study 21709093 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin (up to 800 mg)
Number of subjects: 95
Study 21709093 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin (400 mg and above)
Number of subjects: 95
Study 21709093 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin
Number of subjects: 95
Study 19590021 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 149
Study 19590021 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study 16289608 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful processing (disengagement from supraliminal dysphoric pictures)
Number of subjects: 0
Study 16289608 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic processing (disengagement from masked pictures depicting threat)
Number of subjects: 0
Study 16289608 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful challenge
Number of subjects: 0
Study 16289608 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 15329112 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release alfuzosin 5 mg twice daily
Number of subjects: 81
Study 15329112 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study 11144370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavac
Number of subjects: 848
Study 11144370 — intervention group
Group type: COMPARATOR
Intervention: Pentavac and H-B-Vax II
Number of subjects: 848
Study 11144370 — intervention group
Group type: COMPARATOR
Intervention: Pentavac
Number of subjects: 848
Study 11144370 — intervention group
Group type: COMPARATOR
Intervention: H-B-Vax II
Number of subjects: 848
Study 9333329 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 10% (200/0.5) at 12 ml per kg body-weight daily
Number of subjects: 25
Study 9333329 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 7936015 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 29
Study 7936015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3330989 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 3330989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 0
Study 31362799 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme Peer-delivered (THPP)
Number of subjects: 850
Study 31362799 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 850
Study 29076400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 40
Study 29076400 — intervention group
Group type: COMPARATOR
Intervention: Total sleep deprivation
Number of subjects: 40
Study 30017258 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy interventions
Number of subjects: 616
Study 28058714 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo‐inositol 1000 mg, Tribulus Terrestris 300 mg, Alga Ecklonia Bicyclis 200 mg and Biovis one tablet a day for 90 days
Number of subjects: 60
Study 28058714 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet a day for 90 days
Number of subjects: 60
Study 26759291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen and Bio‐Gide
Number of subjects: 16
Study 26759291 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous healing)
Number of subjects: 16
Study 26759291 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro‐computed tomography results
Number of subjects: 16
Study 24490577 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangzhikangyanghua mixture 20 mL tid + amlodipine 5 mg qd + valsartan 80 mg qd
Number of subjects: 72
Study 24490577 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg qd + valsartan 80 mg qd
Number of subjects: 72
Study 21328025 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (1.5 μg/kg) injected for 14 consecutive days
Number of subjects: 40
Study 18294600 — intervention group
Group type: EXPERIMENTAL
Intervention: Living dog (Dog)
Number of subjects: 0
Study 18294600 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic dog (AIBO)
Number of subjects: 0
Study 18294600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AAT)
Number of subjects: 0
Study 16782490 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed clamping (2 min after delivery of the infant's shoulders)
Number of subjects: 476
Study 16782490 — intervention group
Group type: COMPARATOR
Intervention: Early clamping (around 10 s after delivery)
Number of subjects: 476
Study 15272957 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to an overweight woman
Number of subjects: 2
Study 15272957 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to heavy individuals
Number of subjects: 2
Study 10999555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 300 mg/d
Number of subjects: 46
Study 10999555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10999555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 46
Study 8979144 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse of nephrotic syndrome
Number of subjects: 89
Study 8979144 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission of nephrotic syndrome
Number of subjects: 89
Study 8979144 — intervention group
Group type: COMPARATOR
Intervention: Healthy age- and sex-matched controls
Number of subjects: 89
Study 1361964 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms GHRH
Number of subjects: 7
Study 1361964 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms SRIF
Number of subjects: 7
Study 1361964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6823952 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita‐Stat automatic blood pressure recorder
Number of subjects: 408
Study 6823952 — intervention group
Group type: COMPARATOR
Intervention: Random-Zero sphygmomanometer
Number of subjects: 408
Study 30656993 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g every 6 hours)
Number of subjects: 37
Study 30656993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30316488 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapist-assisted acceptance-based behavioral intervention (Surviving and Thriving During Stress)
Number of subjects: 0
Study 30316488 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 26867802 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (YG)
Number of subjects: 163
Study 26867802 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (ST)
Number of subjects: 163
Study 26867802 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 163
Study 25251999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 25 µg/kg (body-weight-adjusted)
Number of subjects: 89
Study 25251999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 50 or 100 μg/kg
Number of subjects: 89
Study 25251999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 6 mg (fixed-dose)
Number of subjects: 89
Study 25251999 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim 100 μg/kg
Number of subjects: 89
Study 25251999 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim 6 mg (fixed-dose)
Number of subjects: 89
Study 21675542 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused self-regulation strategies (e.g., comfort seeking)
Number of subjects: 117
Study 21675542 — intervention group
Group type: EXPERIMENTAL
Intervention: Planful self-regulation strategies (e.g., distraction)
Number of subjects: 117
Study 21675542 — intervention group
Group type: EXPERIMENTAL
Intervention: Trajectory analysis of emotional SRS
Number of subjects: 117
Study 19532850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen and naloxone infusion (0.25 microg/kg/h for 48 hours)
Number of subjects: 10
Study 19532850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen and naloxone infusion
Number of subjects: 10
Study 19532850 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (historical controls)
Number of subjects: 10
Study 16765847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil (SO) 5 ml by mouth at bedtime
Number of subjects: 107
Study 16765847 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5 ml by mouth at bedtime
Number of subjects: 107
Study 15325416 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg body weight
Number of subjects: 0
Study 15325416 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg/kg body weight
Number of subjects: 0
Study 15325416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11216930 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (H) for 6 months
Number of subjects: 1053
Study 11216930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus pyrazinamide (RZ) for 3 months
Number of subjects: 1053
Study 11216930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1053
Study 11216930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis (associated with mortality)
Number of subjects: 1053
Study 9257377 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinol preparation
Number of subjects: 0
Study 9257377 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E cream
Number of subjects: 0
Study 8382234 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (231 patients, 5-10 mg/day)
Number of subjects: 461
Study 8382234 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (230 patients, 10-40 mg/day)
Number of subjects: 461
Study 3791659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (1.5 ml/kg initial dose, maintained at 110-140 mg%)
Number of subjects: 8
Study 3791659 — intervention group
Group type: COMPARATOR
Intervention: Control day (no ethanol ingestion)
Number of subjects: 8
Study 1124370 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal selective vagotomy with pyloroplasty
Number of subjects: 35
Study 1124370 — intervention group
Group type: COMPARATOR
Intervention: Proximal selective vagotomy without pyloroplasty
Number of subjects: 35
Study 31898656 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdigitated HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Number of subjects: 82
Study 31898656 — intervention group
Group type: COMPARATOR
Intervention: Sequential HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Number of subjects: 82
Study 28804455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathode placed on left DLPFC
Number of subjects: 0
Study 28804455 — intervention group
Group type: COMPARATOR
Intervention: Cathode placed on shoulder
Number of subjects: 0
Study 25332169 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of rTMS (n = 19)
Number of subjects: 34
Study 25332169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten sessions of low-frequency rTMS (n = 15)
Number of subjects: 34
Study 23136031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade of ACEI and ARB (subgroup AA)
Number of subjects: 148
Study 23136031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered dialysate sodium concentration from 140 mmol/l to 138 mmol/l
Number of subjects: 148
Study 23136031 — intervention group
Group type: COMPARATOR
Intervention: ACEI (subgroup A)
Number of subjects: 148
Study 21640057 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledentistry examination
Number of subjects: 234
Study 21640057 — intervention group
Group type: COMPARATOR
Intervention: Traditional visual/tactile oral examination
Number of subjects: 234
Study 19996424 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone-artesunate (CDA) 2.0/2.5/4.0 mg/kg, once daily for 3 days
Number of subjects: 892
Study 19996424 — intervention group
Group type: COMPARATOR
Intervention: Chlorproguanil-dapsone (CPG-DDS) 2.0/2.5 mg/kg, once daily for 3 days
Number of subjects: 892
Study 19996424 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA in G6PD-deficient patients
Number of subjects: 892
Study 19996424 — intervention group
Group type: COMPARATOR
Intervention: CPG-DDS in G6PD-deficient patients
Number of subjects: 892
Study 19996424 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA in G6PD-normal patients
Number of subjects: 892
Study 19996424 — intervention group
Group type: COMPARATOR
Intervention: CPG-DDS in G6PD-normal patients
Number of subjects: 892
Study 16997506 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy-related typing
Number of subjects: 842
Study 16997506 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhi-guang Xie typing system
Number of subjects: 842
Study 16997506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1992 Fuzhou staging system
Number of subjects: 842
Study 15534546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating platform tibia group
Number of subjects: 240
Study 15534546 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular metal-backed group
Number of subjects: 240
Study 15534546 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene group
Number of subjects: 240
Study 15534546 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized, fixed-bearing knee (control)
Number of subjects: 240
Study 11333852 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based dietary treatment with locally available foods and micronutrient supplements
Number of subjects: 141
Study 11333852 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 141
Study 9005975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) 2 microg/kg IV
Number of subjects: 6
Study 9005975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) combined with GHRH (2 microg/kg IV)
Number of subjects: 6
Study 9005975 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human GH (rhGH) 2 U IV
Number of subjects: 6
Study 9005975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) combined with pyridostigmine (PD) 120 mg orally
Number of subjects: 6
Study 9005975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) combined with GHRH and PD
Number of subjects: 6
Study 9005975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) combined with GHRH
Number of subjects: 6
Study 8504051 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms/g calcitriol ointment applied twice daily
Number of subjects: 32
Study 8504051 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 32
Study 3123600 — intervention group
Group type: EXPERIMENTAL
Intervention: R-(-)-deprenyl
Number of subjects: 30
Study 3123600 — intervention group
Group type: COMPARATOR
Intervention: methixene
Number of subjects: 30
Study 29479099 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine periodontal treatment methods for streptococcal gingivitis
Number of subjects: 16
Study 29479099 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment with antacid chewing tablet two times a day for a week
Number of subjects: 16
Study 26494831 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863 (0.5 mg, 2 mg, or 5 mg)
Number of subjects: 0
Study 26494831 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863 (5 mg)
Number of subjects: 0
Study 26494831 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin
Number of subjects: 0
Study 26494831 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863
Number of subjects: 0
Study 24788501 — intervention group
Group type: EXPERIMENTAL
Intervention: Targon Femoral Neck (TFN) hip screw
Number of subjects: 174
Study 24788501 — intervention group
Group type: COMPARATOR
Intervention: Cannulated screw fixation
Number of subjects: 174
Study 23024236 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulated individualized suction (range: -11 to -20 cmH2O)
Number of subjects: 100
Study 23024236 — intervention group
Group type: COMPARATOR
Intervention: Regulated seal (-2 cmH2O)
Number of subjects: 100
Study 20334692 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 70
Study 20334692 — intervention group
Group type: COMPARATOR
Intervention: Arts/social programme
Number of subjects: 70
Study 18982209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 8
Study 16352688 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg daily for 2 months
Number of subjects: 24
Study 15004772 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional VVB
Number of subjects: 67
Study 15004772 — intervention group
Group type: EXPERIMENTAL
Intervention: Piggyback LT
Number of subjects: 67
Study 10646878 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (FLU)
Number of subjects: 310
Study 10646878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA)
Number of subjects: 310
Study 9058444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PPN Group (SG, n = 19)
Number of subjects: 41
Study 9058444 — intervention group
Group type: COMPARATOR
Intervention: Modified Group (MG, n = 22)
Number of subjects: 41